These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 25723165)

  • 41. Marburg virus VP35 can both fully coat the backbone and cap the ends of dsRNA for interferon antagonism.
    Bale S; Julien JP; Bornholdt ZA; Kimberlin CR; Halfmann P; Zandonatti MA; Kunert J; Kroon GJ; Kawaoka Y; MacRae IJ; Wilson IA; Saphire EO
    PLoS Pathog; 2012 Sep; 8(9):e1002916. PubMed ID: 23028316
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein.
    Kajihara M; Marzi A; Nakayama E; Noda T; Kuroda M; Manzoor R; Matsuno K; Feldmann H; Yoshida R; Kawaoka Y; Takada A
    J Virol; 2012 Dec; 86(24):13467-74. PubMed ID: 23035224
    [TBL] [Abstract][Full Text] [Related]  

  • 43. De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses.
    Wang D; Schmaljohn AL; Raja NU; Trubey CM; Juompan LY; Luo M; Deitz SB; Yu H; Woraratanadharm J; Holman DH; Moore KM; Swain BM; Pratt WD; Dong JY
    Vaccine; 2006 Apr; 24(15):2975-86. PubMed ID: 16530297
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Filovirus proteins for antiviral drug discovery: A structure/function analysis of surface glycoproteins and virus entry.
    Martin B; Hoenen T; Canard B; Decroly E
    Antiviral Res; 2016 Nov; 135():1-14. PubMed ID: 27640102
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mechanism of differential Zika and dengue virus neutralization by a public antibody lineage targeting the DIII lateral ridge.
    Zhao H; Xu L; Bombardi R; Nargi R; Deng Z; Errico JM; Nelson CA; Dowd KA; Pierson TC; Crowe JE; Diamond MS; Fremont DH
    J Exp Med; 2020 Feb; 217(2):. PubMed ID: 31757867
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Longitudinal proteome-wide antibody profiling in Marburg virus survivors identifies wing domain immunogen for vaccine design.
    Khurana S; Grubbs G; Ravichandran S; Cluff E; Kim J; Kuehne AI; Zak S; Dye JM; Lutwama JJ; Herbert AS
    Nat Commun; 2024 Sep; 15(1):8133. PubMed ID: 39285186
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular architecture of the nucleoprotein C-terminal domain from the Ebola and Marburg viruses.
    Baker LE; Ellena JF; Handing KB; Derewenda U; Utepbergenov D; Engel DA; Derewenda ZS
    Acta Crystallogr D Struct Biol; 2016 Jan; 72(Pt 1):49-58. PubMed ID: 26894534
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors.
    Kuzmina NA; Younan P; Gilchuk P; Santos RI; Flyak AI; Ilinykh PA; Huang K; Lubaki NM; Ramanathan P; Crowe JE; Bukreyev A
    Cell Rep; 2018 Aug; 24(7):1802-1815.e5. PubMed ID: 30110637
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunogenicity.
    Hood CL; Abraham J; Boyington JC; Leung K; Kwong PD; Nabel GJ
    J Virol; 2010 Mar; 84(6):2972-82. PubMed ID: 20053739
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comprehensive analysis of ebola virus GP1 in viral entry.
    Manicassamy B; Wang J; Jiang H; Rong L
    J Virol; 2005 Apr; 79(8):4793-805. PubMed ID: 15795265
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Virion-Based Assay for Glycoprotein Thermostability Reveals Key Determinants of Filovirus Entry and Its Inhibition.
    Bortz RH; Wong AC; Grodus MG; Recht HS; Pulanco MC; Lasso G; Anthony SJ; Mittler E; Jangra RK; Chandran K
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32611759
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Surrogate Animal Model for Screening of Ebola and Marburg Glycoprotein-Targeting Drugs Using Pseudotyped Vesicular Stomatitis Viruses.
    Saito T; Maruyama J; Nagata N; Isono M; Okuya K; Takadate Y; Kida Y; Miyamoto H; Mori-Kajihara A; Hattori T; Furuyama W; Ogawa S; Iida S; Takada A
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32842671
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Structural basis for Marburg virus VP35-mediated immune evasion mechanisms.
    Ramanan P; Edwards MR; Shabman RS; Leung DW; Endlich-Frazier AC; Borek DM; Otwinowski Z; Liu G; Huh J; Basler CF; Amarasinghe GK
    Proc Natl Acad Sci U S A; 2012 Dec; 109(50):20661-6. PubMed ID: 23185024
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Structural Basis of Pan-Ebolavirus Neutralization by an Antibody Targeting the Glycoprotein Fusion Loop.
    Murin CD; Bruhn JF; Bornholdt ZA; Copps J; Stanfield R; Ward AB
    Cell Rep; 2018 Sep; 24(10):2723-2732.e4. PubMed ID: 30184505
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mapping of Ebolavirus Neutralization by Monoclonal Antibodies in the ZMapp Cocktail Using Cryo-Electron Tomography and Studies of Cellular Entry.
    Tran EE; Nelson EA; Bonagiri P; Simmons JA; Shoemaker CJ; Schmaljohn CS; Kobinger GP; Zeitlin L; Subramaniam S; White JM
    J Virol; 2016 Sep; 90(17):7618-27. PubMed ID: 27279622
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses.
    Stonier SW; Herbert AS; Kuehne AI; Sobarzo A; Habibulin P; Dahan CVA; James RM; Egesa M; Cose S; Lutwama JJ; Lobel L; Dye JM
    J Exp Med; 2017 Sep; 214(9):2563-2572. PubMed ID: 28724616
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Structure of HCMV glycoprotein B in the postfusion conformation bound to a neutralizing human antibody.
    Chandramouli S; Ciferri C; Nikitin PA; Caló S; Gerrein R; Balabanis K; Monroe J; Hebner C; Lilja AE; Settembre EC; Carfi A
    Nat Commun; 2015 Sep; 6():8176. PubMed ID: 26365435
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor.
    Lee JE; Fusco ML; Hessell AJ; Oswald WB; Burton DR; Saphire EO
    Nature; 2008 Jul; 454(7201):177-82. PubMed ID: 18615077
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.
    Kimble JB; Malherbe DC; Meyer M; Gunn BM; Karim MM; Ilinykh PA; Iampietro M; Mohamed KS; Negi S; Gilchuk P; Huang K; Wolf YI; Braun W; Crowe JE; Alter G; Bukreyev A
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30518655
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Structure of an antibody in complex with its mucin domain linear epitope that is protective against Ebola virus.
    Olal D; Kuehne AI; Bale S; Halfmann P; Hashiguchi T; Fusco ML; Lee JE; King LB; Kawaoka Y; Dye JM; Saphire EO
    J Virol; 2012 Mar; 86(5):2809-16. PubMed ID: 22171276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.